Skip to main content
. 2023 Aug 3;15(15):3957. doi: 10.3390/cancers15153957

Figure 2.

Figure 2

CSC suppression by CB-103 alone or in combination second line endocrine therapies. CB-103 suppresses mammosphere formation alone and in combination with fulvestrant in wild type MCF-7 cells (A) and two distinct endocrine-resistant models, T47D/PKCα (B) and WHM20, PDX-derived cells expressing mutant ESR1-Y537S (C). In the ESR1 Y537S mutant line (D) CB-103 plus Palbociclib also shows potent inhibition of mammosphere formation. The concentration of each drug used is indicated under each bar according to x-axis legend. Statistical significance upon one-way ANOVA with Bonferroni correction for multiple comparisons is shown on each histogram with * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.